H2020 Strategy

CIC bioGUNE Strategic Plan for Research and Innovation is designed to provide the framework that allows CIC bioGUNE scientists to perform high-quality interdisciplinary scientific research that reaches society, attracts talent and external funding, and permits the center to be internationally recognized.

Therefore, with our Strategic Plan for H2020, we are committed to Excellence Science, Societal Challenges, and Industrial leadership. We fully unroll the potential of our research breakthroughs for the wellbeing of Society.

CIC bioGUNE is also integrated into the Strategic Plan for Smart Specialization for Research and Innovation (RIS3) at the Regional, National, and Marco Areas.

In particular, RIS3 for BioScience is a strategic bet for the Basque Region and builds on location, regional research and production strengths, involving all of the key actors in our Society, including business, research, government and other civil bodies. Since building on research and production strengths is important, clustering and entrepreneurship are both key priorities as objectives. CIC bioGUNE emphasizes the effective co-ordination between the different societal stakeholders and rationalizes the available resources providing defined strategies to foster initiatives between private and public actors of different governance levels.

RIS3 Euskadi

Orkestra Spri Innobasque

CIC bioGUNE is fully integrated into the RIS3 programme, leading the working group in Rare Diseases, and also actively participating in all priority areas of the region into the H2020 framework.

For more information follow this link

Horizon H2020

Excellent Science
European Commission
  • Breaking the limits in glycan recognition by NMR - RECGLYCANMR
    Jesús Jiménez Barbero: Advanced Grant
  • Targeting the adaptive capacity of prostate cancer through the manipulation of transcriptional and metabolic traits - CancerADAPT
    Arkaitz Carracedo: Consolidator Grant
  • Exploiting the hypoxia response in T cells for Next Generation Immuno-Oncology - NextGen IO
    Asís Palazón: Starting Grant
  • Elucidating the Molecular Mechanisms of Synthetic Saponin Adjuvants and Development of Novel Self-Adjuvanting Vaccines - Adjuv-ant Vaccines
    Alberto Fernández Tejada: Starting Grant
  • A metabolism bases prognostic biomarker for prostate cancer - MetaboMARKER
    Arkaitz Carracedo: Proof of Concept
  • Metabolic Requirements for prostate cancer cell fitness - Cancermetab
    Arkaitz Carracedo: Starting Grant

Marie Skłodowska-Curie actions Marie Curie Actions

Individual Fellowship
  • Target identification and elucidation of the molecular mechanism of action of saponin vaccine adjuvants QS-21 - QS21Mech
    Abhijit Saha (Standard European Fellowship)
  • Chemoenzymatic glyco-engineering of therapeutic monoclonal antibodies (GlycoMabs)
    Beatriz Trastoy (European Reintegration Fellowship)
  • First Chemoselective Synthesis and Structural Studies of Lasso Peptides - FCSSSLP)
    Javier López Ogalla (Global Fellowship)
  • Novel vaccine and diagnostic strategies against Schmallenberg virus - SchmaVirusVacDiag)
    Hani Yousef (European Standard Fellowship)
  • Cholesterol metabolism as a driver of prostate cancer aggressiveness - ACM
    Alfredo Caro (Standard European Fellowship)
  • Implication of energy sensing pathways in prostate cancer biology - PTENLKB1
    Arkaitz Carracedo (International Reintegration Grants 7th Framework Programme)
  • Unravellin the Nascent Code: Signals sensed and transmitted by the nascent chain to acquire its functional state or reprogram gene expression - NascentCode
    Paola Fucini (Career Integration Grants 7th Framework Program)
Innovative Training Networks (TN)
  • Anti-Bacterial Innovative Vaccine Training Network - BactiVax
    Jesús Jiménez Barbero & Juan Anguita
  • The life cycle of extracellular vesicles in prostate cancer: from biogenesis and homing, to functional relevance - proEVLifeCycle
    Juan Manuel Falcón Pérez
  • European Research Training to Decipher the Ub Code: identification of potencial biomarkers nad drug targets - UbiCODE
    Rosa Barrio
  • Tribbles Research and Innovation Network - Train
    Arkaitz Carracedo
  • A training network for the rational design of the next generation of well-defined glycoconjugate vaccines - Glycovax
    Jesús Jiménez-Barbero
  • Toll-Like Receptor 4 activation and function in diseases: an integrated chemical-biology approach - TOLLerant
    Jesús Jiménez Barbero
  • European Research Training in the Ubiquitin Proteasome System - UPStream
    Rosa Barrio (Coordinator)

Societal Challenges

Health, demografic change and wellbeing
Innovative Medicine Initiative (IMI)
  • Liver Investigation: Testing Marker Utility in Steatohepatitis - LITMUS
    José María Mato
  • Anti-tick Vaccines to Prevent Tick-borne Diseases in Europe - Antidote
    Juan Anguita (Health Innovation 7th Framework Programme)
  • Hepatic and adipose tissue and functions in the metabolic syndrome - Hepadip
    José María Mato (Life Science Health 6th Framework Programme)
7th Framework Programme – COOPERATION
  • Integration of novel NANOparticle based technology for THERapeutics and diagnosis of different types of cancer - Nanother
    Edurne Berra
Innovative Medicine Initiative

European Partnerships

Joint Transnational Call - ERA PerMed
  • Plasma extracellular vesicles (EVs): the key for precision medicine in Glioblastoma – EV-glio
    Juan Manuel Falcón
European Joint Programme on Rare Disease (EJP RD)
  • For Improving diagnostics and the disease mechanisms of rare Hypomagnesemia in paTients with CNNM2 mutations - FIGHT-CNNM2
    Alfonso Martínez

Interreg EUROPE

  • Red cooperativa franco-española para el análisis de proteinopatías y el desarrollo de terapias individualizadas en cánceres hematológicos - PROTEOblood
    Rosa Barrio
  • Red de investigación transfronteriza en enfermedades priónicas humanas y animales – REDPRION
    Joaquín Castilla

European Cooperation

European Cooperation in Science and Technology (COST)

  • European network to integrate research on intracellular proteolysis pathways in health and disease - Proteostasis
    Rosa Barrio (Chair)
European Cooperation in Science and Technology

To take part in our collaborative efforts towards H2020 strategy, please contact directly our research staff or R&D Management Office: